Language
English
Publication Date
5-1-2024
Journal
European Respiratory Journal
DOI
10.1183/13993003.00150-2024
PMID
38485148
Abstract
Globally, nearly 400 million persons have COPD, and COPD is one of the leading causes of hospitalisation and mortality across the world. While it has been long-recognised that COPD is an inflammatory lung disease, dissimilar to asthma, type 2 inflammation was thought to play a minor role. However, recent studies suggest that in approximately one third of patients with COPD, type 2 inflammation may be an important driver of disease and a potential therapeutic target. Importantly, the immune cells and molecules involved in COPD-related type 2 immunity may be significantly different from those observed in severe asthma. Here, we identify the important molecules and effector immune cells involved in type 2 airway inflammation in COPD, discuss the recent therapeutic trial results of biologicals that have targeted these pathways and explore the future of therapeutic development of type 2 immune modulators in COPD.
Keywords
Pulmonary Disease, Chronic Obstructive, Humans, Inflammation, Th2 Cells, Asthma
Published Open-Access
yes
Recommended Citation
Francesca Polverino and Don D Sin, "Type 2 Airway Inflammation in COPD" (2024). Faculty, Staff and Students Publications. 6363.
https://digitalcommons.library.tmc.edu/baylor_docs/6363